Keystone Bio is developing a first‐of‐kind bio‐therapeutic, and a new suite of diagnostics, therapeutics, and monoclonal antibodies in the multi‐billion‐dollar arena of Alzheimer’s and Heart Disease.
Keystone Bio is initiating Phase I/II clinical trials for its proprietary first-of-kind bio-therapeutic-drug for heart disease targeting volatile coronary artery plaque and post-event myocardium vulnerability.
“We have known for some time that what is good for your heart is good for your head.”
Research Committee Manager
Alzheimer’s Society UK